目的 探讨应用脐带间充质干细胞移植治疗脑瘫患儿流涎症的疗效。方法 25例脑瘫合并流涎症患儿被随机分入实验组和对照组。实验组每位患儿接受4次腰椎穿刺干细胞移植术,对照组不给予任何手术及药物干预治疗,实验组于移植前及移植后1、3、6个月进行流涎频率及严重程度评分(SF)、唾液称重(W)、流涎商测定(DQ)。对照组于入组时及入组后1、3、6个月分别行SF、W、DQ评定。结果 实验组与对照组相比较,实验组SF、DQ在术后1、3、6个月均明显低于对照组(P<0.05),差异具有统计学意义;SF指标显示术后1、3、6个月治愈率分别为61.54%、23.08%、23.08%;DQ指标显示术后1、3、6个月治愈率分别为69.23%、46.15%、23.08%;SF、DQ术后1、3、6个月有效率均为69.23%。W指标显示术后1、3个月,实验组明显低于对照组(P<0.05),差异具有统计学意义,术后1、3个月实验组治愈率分别为69.23%、38.46%,有效率均为69.23%;术后6个月实验组与对照组差异不具有统计学意义,但实验组患儿个体比较,术后6个月与术前相比治愈率为23.08%,有效率为69.23%。结论 脐带间充质干细胞移植可以显著改善脑瘫患儿流涎症,从而提高患儿生活质量。
Abstract
Objective To observe the clinical effect of umbilical cord mesenchymal stem cells transplantation on drooling of cerebral palsy patients.Methods Twenty-five cases of cerebral palsy children with drooling were randomly assigned into the experimental group and control group. Each child in the experimental group accepted four times of stem cells transplantation via lumbar puncture, while patients in the control group were given neither surgery nor drug intervention. The frequency and severity (FS) of drooling,saliva weight (W),and drooling quotient (DQ)in both groups were assessed one, three and six months before and after transplantation respectively.Results SF and DQ of the experimental group one, three and six months after transplantation were significantly lower than in the control group (P<0.05), and the difference was statistically significant. SF indicated that one, three and six months after transplantation the cure rate was 61.54%, 23.08% and 23.08% respectively. DQ suggested that the cure rate was 69.23%, 46.15% and 23.08% respectively. SF and DQ showed that the efficacy rate one, three and six months after transplantation was 69.23%. One and three months postoperatively, the value of W was significantly lower than that of the control group (P<0.05). One and three months after transplantation, the cure rates were 69.23% and 38.46% respectively in the experimental group.Six months after transplantation, there was no statistically significant difference between the experimental group and control group. However, the cure rate of the experimental group six months postoperatively was 23.08%, and the efficacy rate was 69.23%.Conclusions The umbilical cord mesenchymal stem cells transplantation can significantly improve the drooling in children with cerebral palsy, thus improving the life quality of patients.
关键词
间充质干细胞 /
脑瘫 /
流涎
Key words
umbilical cord mesenchymal stem cells /
cerebral palsy /
drooling
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Hustad K C, Gorton K, Lee J. Classification of speech and language pro-files in 4- year- old children with cerebral palsy: a prospective prelimi-nary study [J]. J Speech Lang Hear Res, 2010, 53(6): 1496-1513.
[2] Thomas-Stonell N, Greenberg J. Three treatment approaches and clinical factors in the reduction of drool-ing [J]. Dysphagia, 1988,3:73-78.
[3] Chang S C, Lin C K, Tung L C, et al. The association of drooling and health-related quality of life in children with cerebral palsy [J]. Neuro-psychiatr Dis Treat, 2012, 8: 599-604.
[4] 李 林.小儿脑性瘫痪流涎症康复治疗研究进展[J]. 中国康复理论与实践, 2009, 15(9): 804-806.
[5] Senner J E, Logemann J, Zecker S, et al. Drooling, saliva production, and swallowing in cerebral palsy [J]. Dev Med Child Neurol, 2004, 46 (12): 801-806.
[6] parr J R, Buswell C A, Banerjee K, et al. Management of drooling in children: a survey of UK paediatricians’ clinical practice [J]. Child Care Health Dev, 2012, 38(2): 287-291.
[7] Dai G, Liu X, Zhang Z, et al. Comparative analysis of curative effect of CT-guided stem cell transplantation and open surgi-cal transplantation for sequelae of spinal cord injury[J]. J Transl Med, 2013, 11:315.
[8] Tiigimae-Saar J, Leibur E, Kolk A, et al. Use of botulinum neurotoxin A in uncontrolled salivation in children with cerebral palsy: a pilot study [J]. Int J Oral Maxillofac Surg, 2012, 41(12): 1540-1545.
[9] Webb K, Reddihough D S, Johnson H. Long-term outcome of saliva-control surgery [J]. Dev Med Child Neurol, 1995,37:755-762.
[10] Lee Z I, Cho D H, Choi W D, et al. Effect of botulinum toxin type A on morphology of salivary glands in patients with cerebral palsy [J]. Ann Rehabil Med, 2011, 35(5): 636-640.
[11] Scheffer A R, Erasmus C, van Hulst K, et al. Efficacy and duration of botulinum toxin treatment for drooling in 131 children [J]. Arch Otolar-yngol Head Neck Surg, 2010, 136(9): 873-877.
[12] Erasmus C E,Van Hulst K,Rotteveel L J, et al. Drooling in cerebral palsy: hypersalivation or dysfunctional oral motor control [J].Dev Med Child Neurol, 2009,51:454-459.
[13] Santos M T, Ferreira M C, Leite M F, et al. Salivary parameters in Brazil-ian individuals with cerebral palsy who drool [J]. Child Care Health Dev, 2011, 37(3): 404-409.
[14] Chang C J, May-Kuen Wong A A. Intraductal laser photocoagulation of the bilateral parotid ducts for reduction of drooling in patients with cerebral palsy [J]. Plast Reconstr Surg, 2001,107(4):907-913.
[15] Mier R J, Bachrach S J, Lakin R C,et al.Treatment of sialorrhea with glycopyrrolate: A double-blind, dose-ranging study [J]. Arch Pediatr Adolesc Med, 2000,154(12):1214-1218.
[16] Holsinger F C, Bui D T. Anatomy, function, and evaluation of the salivary glands [J]. Salivary Glands Disorders, 2007, 1: 1-16.
[17] Julie A Y,Bruce E.Dysphagia:Foundation,Theory and practice[M]. England:John Wiley & Sons Ltd, West Sussex, 2006: 126.
[18] Senner J E, Logemann J, Zecker S, et al. Drooling, saliva production, and swallowing in cerebral palsy [J]. Dev Med Child Neurol, 2004, 46 (12): 801-806.
[19] puraviappan P, Dass D B, Narayanan P. Efficacy of relocation of sub-mandibular duct in cerebral palsy patients with drooling [J]. Asian J Surg, 2007, 30(3): 209-215.
[20] Siegel L K, Klingbeil M A. Control of drooling with transdermal scopolamine in a child with cerebral palsy [J]. Dev Med Child Neurol, 1991,33:1013-1014.
[21] Camp-Bruno J A, Winsberg B G, Green-parsons A R, et al. Efficacy of benztropine therapy for drooling [J]. Dev Med Child Neurol,1989,31:309-319.
[22] Tiigimae-Saar J, Leibur E, Kolk A, et al. Use of botulinum neurotoxin A in uncontrolled salivation in children with cerebral palsy: a pilot study [J]. Int J Oral Maxillofac Surg, 2012, 41(12): 1540-1545.
[23] Basciani M, Di Rienzo F, Fontana A, et al. Botulinum toxin type B for sialorrhoea in children with cerebral palsy: a randomized trial comparing three doses [J]. Dev Med Child Neurol, 2011,53(6):488-489.
[24] porte M, Chaléat-Valayer E, patte K, et al. Relevance of intraglandular injections of Botulinum toxin for the treatment of sialorrhea in children with cerebral palsy: a review [J]. Eur J paediatr Neurol, 2014, 18(6): 649-657.
[25] Rodwell K, Edwards P, Ware R S, et al. Salivary gland botulinum toxin injections for drooling in children with cerebral palsy and neurodevelop-mental disability: a systematic review [J]. Dev Med Child Neurol, 2012, 54(11): 977-987.
[26] Wang X, Cheng H, Hua R, et al. Effects of bone marrow mes-enchymal stromal cells on gross motor function measure scores of children with cerebral palsy: a preliminary clinical study[J]. Cytotherapy, 2013, 15(12):1549-1562.
[27] Wang L, Ji H, Zhou J, et al. Therapeutic potential of umbili-cal cord mesenchymal stromal cells transplantation for cere-bral palsy: a case report[J]. Case Rep Transplant, 2013, 2013: 146347.
[28] Chen G, Wang Y, Xu Z, et al. Neural stem cell-like cells de-rived from autologous bone mesenchymal stem cells for the treatment of patients with cerebral palsy[J]. J Transl Med, 2013, 11:21.
基金
广东省战略性新兴产业核心技术攻关项目(2011A081401003)
PDF(718 KB)
